We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PROSTACOX : Metastatic Prostate Chemotherapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00213694
First Posted: September 21, 2005
Last Update Posted: March 5, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital, Rouen
  Purpose
Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.

Condition Intervention Phase
Metastatic Prostate Cancer Drug: docetaxel and celecoxib Phase 2

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer

Resource links provided by NLM:


Further study details as provided by University Hospital, Rouen:

Estimated Enrollment: 52
Study Start Date: November 2003
Estimated Study Completion Date: June 2006
Detailed Description:
Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • metastatic prostate cancer
  • ASCO progression criteria

Exclusion Criteria:

  • other prostate chemotherapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213694


Locations
France
Charles Nicolle, University Hospital
Rouen, France, 76031
Sponsors and Collaborators
University Hospital, Rouen
Investigators
Principal Investigator: Christian PFISTER, MD, PhD University Hospital, Rouen
  More Information

ClinicalTrials.gov Identifier: NCT00213694     History of Changes
Other Study ID Numbers: 2003/052/HP
First Submitted: September 13, 2005
First Posted: September 21, 2005
Last Update Posted: March 5, 2013
Last Verified: March 2013

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Docetaxel
Celecoxib
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents